Winebrenner Capital Management LLC Makes New $478,000 Investment in Eli Lilly and Company (NYSE:LLY)

Winebrenner Capital Management LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 619 shares of the company’s stock, valued at approximately $478,000.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Navellier & Associates Inc. boosted its holdings in shares of Eli Lilly and Company by 4.1% in the 4th quarter. Navellier & Associates Inc. now owns 25,998 shares of the company’s stock valued at $20,070,000 after buying an additional 1,027 shares during the period. Wealth Management Nebraska acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $203,000. Prentice Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 3.8% in the 4th quarter. Prentice Wealth Management LLC now owns 1,206 shares of the company’s stock valued at $931,000 after buying an additional 44 shares during the period. Deseret Mutual Benefit Administrators boosted its holdings in shares of Eli Lilly and Company by 3.7% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 3,107 shares of the company’s stock valued at $2,399,000 after buying an additional 112 shares during the period. Finally, Variant Private Wealth LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $218,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.1 %

NYSE LLY opened at $874.12 on Friday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The company’s 50 day simple moving average is $801.33 and its 200 day simple moving average is $847.13. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The company has a market capitalization of $828.82 billion, a P/E ratio of 74.65, a PEG ratio of 1.40 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its board has approved a share repurchase program on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 2% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a $1.50 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s payout ratio is presently 51.24%.

Analysts Set New Price Targets

Several research analysts have recently commented on LLY shares. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Bank of America reissued a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Citigroup reduced their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Finally, Truist Financial boosted their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,000.28.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.